

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Rainbow Children's Medicare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Rainbow Children's Medicare Limited (the "Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004
per Atin Bhargava
Partner

Membership No.: 504777

UDIN: 25504117BMOCN08058

Place : Hyderabad

Date: July 26, 2025



Rainbow Children's Medicare Limited				
CIN: L85110TG1998PLC029914				
Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034				
Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in				
Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2025				
(Rs. in Million except per share data)				
Particulars	Quarter ended		Year ended	
	30 June 2025	31 March 2025	30 June 2024	31 March 2025
	Unaudited	Audited	Unaudited	Audited
1. Income				
a. Revenue from operations	3,347.48	3,539.95	3,150.23	14,545.07
b. Other income	192.85	138.95	114.82	489.49
Total income	3,540.33	3,678.90	3,265.05	15,034.56
2. Expenses				
a. Cost of materials consumed	439.50	444.51	412.61	1,898.69
b. Employee benefits expense	492.36	518.47	470.55	1,976.08
c. Finance costs	173.93	174.15	174.39	695.94
d. Depreciation and amortisation expense	325.93	325.48	324.38	1,317.48
e. Professional fees to doctors	867.81	895.80	797.76	3,484.90
f. Other expenses	552.60	573.03	569.07	2,440.64
Total expenses	2,852.13	2,931.44	2,748.76	11,813.73
3. Profit before tax [1-2]	688.20	747.46	516.29	3,220.83
4. Tax expenses				
a. Current tax	168.65	190.46	151.38	856.68
b. Deferred tax	5.81	8.31	(22.36)	(31.54)
c. Adjustment of tax relating to earlier periods	(3.46)	3.29	-	19.84
Total tax expense	171.00	202.06	129.02	844.98
5. Profit after tax [3-4]	517.20	545.40	387.27	2,375.85
6. Other comprehensive income				
Items that will not be reclassified subsequently to the Statement of Profit or Loss				
a. Re-measurement (loss) / gain on defined benefit obligation	(0.72)	38.57	1.21	(2.88)
b. Income tax effect	0.18	(9.71)	(0.30)	0.72
Other comprehensive income (net of tax)	(0.54)	28.86	0.91	(2.16)
7. Total comprehensive income [5+6]	516.66	574.26	388.18	2,373.69
8. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.52	1,015.52	1,015.02	1,015.52
9. Other equity				13,869.92
10. Earning per share (Face value of Rs.10 each)				
a. Basic (Rs)	5.09	5.37	3.82	23.40
b. Diluted (Rs)	5.09	5.37	3.82	23.27
	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- 1 The above statement of unaudited standalone financial results of Rainbow Children's Medicare Limited ("the Company"), which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 26 July 2025. The statutory auditors have carried out a limited review on the unaudited standalone financial results and issued an unmodified report thereon.
- 2 The standalone figures for the fourth quarter ended 31 March 2025 are the balancing figures between published audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year.
- 3 Final dividend for the financial year 2024-25 of Rs. 3 per Equity Share of Rs. 10 each aggregating to Rs. 304.66 million was approved by the shareholders at the 27th Annual General Meeting held on 05 July 2025 and the same was paid on 05 July 2025.
- 4 Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option.

The Nomination and Remuneration Committee ("NRC") of the Company in its meeting held on 26 July 2025, granted 140,810 Stock options under the ESOP 2025 to its eligible employees which shall be exercisable into 140,810 equity shares having face value of Rs.10 each fully paid-up. The Exercise price per stock option shall be determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, being the stock exchange with the highest trading volume, as on 25 July 2025 i.e., the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options shall vest after the minimum vesting period of 1 year and not later than the maximum period of 10 years from the date of grant. The vested Stock options shall be exercisable within a period of maximum of 2 years from the date of each vesting.

- 5 Pursuant to the resolution passed by the Business Strategy and Investment Committee in its meeting held on 28 June 2025, the Company executed the Securities Subscription Agreement and Shareholders Agreement for acquisition of 76% of fully diluted equity share capital and 100% of Non-Convertible Redeemable Preference shares ("NCRPS") of M/s. Prashanthi Medicare Private Limited ("Prashanthi Hospital") which operates 100 beds hospital at Warangal, Telangana for an aggregate cash consideration of Rs. 326.00 million. On 01 July 2025, the Company completed the acquisition of 76% of the fully diluted equity share capital and 100% of the NCRPS of Prashanthi Hospital, pursuant to which it became a subsidiary of the Company.
- 6 The Company is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the Company are concentrated in India, and hence, the Company is considered to operate only in one geographical segment.
- 7 The standalone financial results for the quarter ended 30 June 2025, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).



for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited

Dr. Ramesh Kancharia
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 26 July 2025

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Rainbow Children's Medicare Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited (the "Holding Company"), its subsidiaries and other consolidating entity (the Holding Company, its subsidiaries and other consolidating entity together referred to as "the Group"), for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Holding company:

Rainbow Children's Medicare Limited

Subsidiaries:

- a. Rainbow Speciality Hospitals Private Limited
- b. Rosewalk Healthcare Private Limited
- c. Rainbow C R O Private Limited
- d. Rainbow Fertility Private Limited
- e. Rainbow Children's Hospital Private Limited
- f. Rainbow Woman & Children's Hospital Private Limited

Other consolidating entity:

Rainbow Children's Hospital Foundation

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes unaudited interim financial results in respect of 6 subsidiaries and 1 other consolidating entity, whose interim financial results reflect total revenues of Rs 192.60 million, total net profit after tax of Rs 20.77 million, total comprehensive income of Rs 21.16 million, for the quarter ended June 30, 2025.

The unaudited interim financial results of these subsidiaries and other consolidating entity have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries and other consolidating entity is based solely on such unaudited interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matter stated in para 6 above is not modified with respect to our reliance on the work done and the financial results certified by the Management.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


per Atin Bhargava
Partner

Membership No.: 504777

UDIN: 255047778M0C NV3400



Place : Hyderabad

Date: July 26, 2025

Rainbow Children's Medicare Limited

CIN: L85110TG1998PLC029914

Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034

Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2025

Particulars	(Rs. in Million except per share data)			
	Quarter ended			Year ended
	30 June 2025	31 March 2025	30 June 2024	31 March 2025
	Unaudited	Audited	Unaudited	Audited
1. Income				
a. Revenue from operations	3,529.29	3,701.07	3,302.17	15,158.66
b. Other income	200.16	145.27	119.34	510.08
Total income	3,729.45	3,846.34	3,421.51	15,668.74
2. Expenses				
a. Cost of materials consumed	474.98	470.41	424.79	1,949.20
b. Employee benefits expense	516.20	543.16	489.98	2,063.67
c. Finance costs	180.78	181.21	181.62	724.55
d. Depreciation and amortisation expense	341.87	341.63	341.43	1,384.40
e. Professional fees to doctors	917.58	944.61	849.64	3,690.21
f. Other expenses	584.30	595.63	600.52	2,556.70
Total expenses	3,015.71	3,076.65	2,887.98	12,368.73
3. Profit before tax [1-2]	713.74	769.69	533.53	3,300.01
4. Tax expenses				
a. Current tax	174.82	194.51	156.53	873.08
b. Deferred tax	4.33	6.35	(20.28)	(35.19)
c. Adjustment of tax relating to earlier periods	(3.46)	3.30	-	19.85
Total tax expense	175.69	204.16	136.25	857.74
5. Profit after tax [3-4]	538.05	565.53	397.28	2,442.27
6. Other comprehensive income				
Items that will not be reclassified subsequently to the Statement of Profit or Loss				
a. Re-measurement (loss)/gain on defined benefit obligation	(0.24)	40.09	1.34	(0.98)
b. Income tax effect	0.09	(10.04)	(0.31)	0.37
Other comprehensive income (net of tax)	(0.15)	30.05	1.03	(0.61)
7. Total comprehensive income [5+6]	537.90	595.58	398.31	2,441.66
Profit after tax attributable to				
Owners of the Company	534.99	563.35	395.33	2,434.24
Non-controlling interests	3.06	2.18	1.95	8.03
Profit after tax	538.05	565.53	397.28	2,442.27
Other comprehensive income attributable to				
Owners of the Company	(0.21)	29.84	1.03	(0.83)
Non-controlling interests	0.06	0.21	0.00	0.22
Other comprehensive income	(0.15)	30.05	1.03	(0.61)
Total comprehensive income attributable to				
Owners of the Company	534.78	593.19	396.36	2,433.41
Non-controlling interests	3.12	2.39	1.95	8.25
Total comprehensive income	537.90	595.58	398.31	2,441.66
8. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.52	1,015.52	1,015.02	1,015.52
9. Other equity				13,666.41
10. Earning per share (Face value of Rs.10 each)				
a. Basic (Rs)	5.27	5.55	3.89	23.97
b. Diluted (Rs)	5.27	5.55	3.89	23.84
	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- 1 The above statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited ("the Company"), its subsidiaries and other consolidating entity (the Company, its subsidiaries and other consolidating entity together referred to as "the Group") which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 26 July 2025. The statutory auditors have carried out a limited review on the unaudited consolidated financial results and issued an unmodified report thereon.
- 2 The consolidated figures for the fourth quarter ended 31 March 2025 are the balancing figures between published audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year.
- 3 Final dividend for the financial year 2024-25 of Rs. 3 per Equity Share of Rs. 10 each aggregating to Rs. 304.66 million was approved by the shareholders at the 27th Annual General Meeting held on 05 July 2025 and the same was paid on 05 July 2025.
- 4 Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option.

The Nomination and Remuneration Committee ("NRC") of the Company in its meeting held on 26 July 2025, granted 140,810 Stock options under the ESOP 2025 to its eligible employees which shall be exercisable into 140,810 equity shares having face value of Rs.10 each fully paid-up. The Exercise price per stock option shall be determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, being the stock exchange with the highest trading volume, as on 25 July 2025 i.e., the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options shall vest after the minimum vesting period of 1 year and not later than the maximum period of 10 years from the date of grant. The vested Stock options shall be exercisable within a period of maximum of 2 years from the date of each vesting.

- 5 Pursuant to the resolution passed by the Business Strategy and Investment Committee in its meeting held on 28 June 2025, the Company executed the Securities Subscription Agreement and Shareholders Agreement for acquisition of 76% of fully diluted equity share capital and 100% of Non-Convertible Redeemable Preference shares ("NCRPS") of M/s. Prashanthi Medicare Private Limited ("Prashanthi Hospital") which operates 100 beds hospital at Warangal, Telangana for an aggregate cash consideration of Rs. 326.00 million. On 01 July 2025, the Company completed the acquisition of 76% of the fully diluted equity share capital and 100% of the NCRPS of Prashanthi Hospital, pursuant to which it became a subsidiary of the Company.
- 6 The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- 7 The consolidated financial results for the quarter ended 30 June 2025, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).
- 8 The unaudited consolidated financial results include the financial results of Rainbow Children's Medicare Limited and the financial results of its subsidiaries, Rainbow C R O Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited, Rainbow Children's Hospital Private Limited and its other consolidating entity, Rainbow Children's Hospital Foundation.

Place : Hyderabad
Date : 26 July 2025



for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited

Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270